Brookline Capital Management Comments on RNTX Q1 Earnings

Rein Therapeutics, Inc. (NASDAQ:RNTX) – Research analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Rein Therapeutics in a report issued on Tuesday, April 8th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of ($0.21) per share for the quarter. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. Brookline Capital Management also issued estimates for Rein Therapeutics’ Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.95) EPS.

Rein Therapeutics Trading Up 9.6 %

Shares of RNTX opened at $1.71 on Friday. The company’s fifty day moving average price is $1.97. The firm has a market capitalization of $37.05 million, a P/E ratio of -0.55 and a beta of 2.12. Rein Therapeutics has a 1 year low of $1.35 and a 1 year high of $7.42.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings data on Monday, April 7th. The company reported ($0.26) earnings per share (EPS) for the quarter.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.